Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

Contributed by: Business Wire

Logo

Tags

Biotechnology

Neurology

Health

Pharmaceutical

Clinical Trials

birtamimab

More Like This

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Prothena Reports First Quarter 2025 Financial Results and Business Highlights

Prothena Announces Corporate Restructuring

Prothena Reports First Quarter 2024 Financial Results and Business Highlights

Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

PR Newswire associated0

PeproMene Bio, Inc. Announces Complete Remission of the Cohort 1 First Patient Treated for Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) in the Phase 1 Clinical Trial of PMB-CT01 (BAFFR-CAR T Cells) at City of Hope